Vaccination against SARS-COV-2: one year after vaccination roll-out in Colombia
Vacunación contra SARS-COV-2: un año después de iniciada en Colombia
Article Sidebar
PDF (Español (España))
FLIP
HTML (Español (España))
EPUB (Español (España))
Main Article Content
Abstract
Introduction: mass vaccination against COVID-19 begun in February 2021. As of February17 2022, 75’732.846 doses had been administered nationwide. Peak vaccination rates were achieved on August 6 2021 when 594.933 doses were administered. Objective: to show the SARS-COV-2 vaccination plan behavior in the period between February 17 2021 and February 17 2022. Methodology: a cross-sectional study was conducted. Data was obtained from the Ministry of Health and Social Protection website, based on the national COVID-19 vaccination plan reports. Results: the highest number of doses (10’117.202) was administered in November 2021, the highest number of second doses (3’469.508) was administered in June, the highest number of single doses (2’322.994), as well as the highest number of doses which completed primary vaccination courses (5’282.778) were applied in July, and the highest number of booster doses (2’390.185). was applied in January 2022. Conclusion: vaccination process follow-up, to understand vaccine effectiveness, likelihood of immune response decrease over time and possible adverse effects, is crucial. Tracking virus mutations detected in the country, affecting vaccine-induced immunity, is also essential.
Keywords:
Downloads
Article Details
References
Qin C, Zhou L, Hu Z, Zhang S, Yang S, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi: 10.1093/cid/ciaa248 DOI: https://doi.org/10.1093/cid/ciaa248
Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020;16(10):1753–1766. doi: 10.7150/ijbs.45134 DOI: https://doi.org/10.7150/ijbs.45134
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med 2020;382(21):1969–1973. doi: 10.1056/NEJMp2005630 DOI: https://doi.org/10.1056/NEJMp2005630
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021;384(14):1372-1374. DOI: https://doi.org/10.1056/NEJMc2101667
Baden LR, El Sahly HM, Essink B, Kotloff K, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389 DOI: https://doi.org/10.1056/NEJMoa2035389
Radbruch A, Chang HD. A long-term perspective on immunity to COVID. Nature. 2021;595:359–360. https://doi.org/10.1038/d41586-021-01557-z DOI: https://doi.org/10.1038/d41586-021-01557-z
Mahallawi W, Alzahrani M, and Alahmadey Z. Durability of the humoral immune response in recovered COVID-19 patients. Saudi J Biol Sci. 2021. doi: 10.1016/j.sjbs.2021.1002.1011 DOI: https://doi.org/10.1016/j.sjbs.2021.02.011
Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595(7867):421–425. doi: 10.1038/s41586-021-03647-4 DOI: https://doi.org/10.1038/s41586-021-03647-4
Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021;595(7867):426–431. doi: 10.1038/s41586-021-03696-9 DOI: https://doi.org/10.1038/s41586-021-03696-9
Alsayb MA, Alsamiri ADD, Makhdoom HQ, et al. Prolonged humoral and cellular immunity in COVID-19-recovered patients. Saudi J Biol Sci 2021;28(7):4010–4015. doi: 10.1016/j.sjbs.2021.04.008 DOI: https://doi.org/10.1016/j.sjbs.2021.04.008
Díaz Pinzón JE. Estimación de la prevalencia del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl. 1):99–102. https://doi.org/10.31260/RepertMedCir.01217372.1115 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1115
Díaz Pinzón JE. Análisis de los resultados del contagio del COVID-19 respecto a su distribución geográfica en Colombia. Repert Med Cir. 2020;29(Núm. Supl. 1):60–64. https://doi.org/10.31260/RepertMedCir.01217372.1082 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1082
Díaz Pinzón JE. Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra el SARS-COV-2 en Colombia. Repert Med Cir. 2021;30(Núm. Supl. 1): 41–45. https://doi.org/10.31260/RepertMedCir.01217372.1227 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1227
Ministerio de Salud y Protección Social. Plan de vacunación nacional contra COVID-19 [Internet]. 2021 [Consultado 2021]. Disponible en: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx13
Díaz Pinzón JE. Cobertura de vacunación contra COVID-19 por esquema en Colombia. Repert Med Cir. 2021;30(Núm. Supl. 1):114-117. https://doi.org/10.31260/RepertMedCir.01217372.1280 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1280
Mahallawi WH, Fakher MH, Alsarani MA, Aljohani RH, AL-Mutabgani SA, Ibrahim NA. A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19-Recovered Patients. Viral Immunol. 2022;35(2):122-128. https://doi.org/10.1089/vim.2021.0108 DOI: https://doi.org/10.1089/vim.2021.0108